Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Optimer Pharmaceuticals, Inc.

http://www.optimerpharma.com/

Latest From Optimer Pharmaceuticals, Inc.

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Early Promise Of NextCure’s Novel IO Candidate Continues To Fade

Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.

Clinical Trials ImmunoOncology

BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

Business Strategies Companies

BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

Business Strategies Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register